The bill amends the Public Health Service Act to let the CDC award supplemental grants to current recipients of grants under section 1501 so they can offer cardiovascular preventive services—screenings, evidence-based education, referrals—and monitor outcomes. It also expands who may receive services to include Secretary‑designated high‑risk women and authorizes provider types beyond existing program sites.
This change is intended to leverage the breast and cervical cancer screening infrastructure to reach women at risk for heart disease, while creating a federal funding stream to scale prevention and build program evaluation capacity at the state and local level.
At a Glance
What It Does
Authorizes the CDC to award supplemental grants to section 1501 grantees for additional preventive services including blood pressure, cholesterol, obesity screening, evidence‑based health education, medical referrals, follow‑up to the extent practicable, and program evaluation. The bill appropriates $250 million covering fiscal years 2027–2031 to carry out these grants.
Who It Affects
Primary recipients are organizations already funded under section 1501 (breast and cervical screening programs), state and local health departments, community health centers and other health entities the Secretary designates, and women identified as eligible—both current section 1501 clients and other Secretary‑specified high‑risk women.
Why It Matters
It formally integrates cardiovascular prevention into an existing women’s screening platform, creates a modest dedicated federal funding envelope, and requires data collection and evaluation—potentially shifting early detection and prevention practices in community settings that serve underserved women.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill gives the CDC authority to provide ‘supplemental grants’ on top of existing section 1501 awards so organizations that screen women for breast and cervical cancer can also offer cardiovascular‑risk services. Those services explicitly include screenings (blood pressure, cholesterol, obesity and other risk factors), health education delivered by a qualified provider tied to measurable outcomes, and referral pathways for medical treatment with an expectation of follow‑up when feasible.
Eligibility is twofold: the bill keeps current section 1501 clients within scope while allowing the Secretary to define additional high‑risk women who should receive services. The Secretary also has discretion to authorize other health care entities as providers, not limiting delivery to only those currently running breast and cervical programs.
The statute requires grantees to monitor and report program activities and outcomes to the Secretary, tying grant awards to evaluation and surveillance efforts.The bill sets a dedicated appropriation ceiling—$250 million across FY2027–2031—to fund the supplemental grants. It also tasks the Government Accountability Office with a study due by September 30, 2027, to estimate program eligibility, describe service trends, identify barriers to access, and analyze the program’s cost‑effectiveness relative to outcomes like blood pressure, cholesterol, diabetes, and obesity.
The Five Things You Need to Know
The CDC may award supplemental grants only to recipients of section 1501 grants, enabling those organizations to add cardiovascular screening, education, referrals, and evaluation activities.
Eligibility extends beyond current section 1501 clients to ‘other women who are high‑risk’ as defined by the Secretary, creating discretionary expansion authority at HHS.
Authorized providers include both entities already operating under section 1501 and other health care entities the Secretary approves, widening the pool of potential service sites.
The bill authorizes $250,000,000 for fiscal years 2027 through 2031 to fund these supplemental grants (a five‑year envelope, not an annual appropriation).
The GAO must deliver a report by September 30, 2027, estimating eligible populations, summarizing service trends, assessing barriers to access, and analyzing cost‑effectiveness tied to patient outcomes.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Allows CDC to award supplemental preventive‑service grants
Subsection (a) creates authority for the CDC Director to award supplemental grants to existing section 1501 grantees. Practically, this is a vehicle to fund pilot or expanded activities that attach cardiovascular prevention onto breast/cervical screening programs. Administrators will need to adapt intake, clinical workflows, and data systems to add new screening types and link patients to follow‑up care.
Defines scope of services: screening and evidence‑based education
The statute specifies screenings (blood pressure, cholesterol, obesity, and other risk factors) and requires health education from a qualified provider aimed at measurable improvements (for example, reductions in blood pressure or weight). That phrasing forces grantees to select evidence‑based interventions with documented metrics and to collect baseline and follow‑up data.
Referral/follow‑up requirements, eligibility, and provider rules
Grantees must provide appropriate medical referrals and, as practicable, follow‑up services; however, the statutory ‘to the extent practicable’ qualifier leaves room for resource‑based limits. Eligibility stays anchored to section 1501 clients but expressly permits the Secretary to add other high‑risk women. The Secretary also can designate additional types of health entities as authorized providers, expanding beyond the original breast/cervical program sites.
Funding authorization
The bill authorizes $250 million for FY2027–2031 to implement the supplemental grants. The authorization sets an overall ceiling but does not prescribe allocation formulas, per‑grant sizes, or match requirements—those will be determined in subsequent CDC grant guidance and appropriations legislation.
GAO study and required analyses
The GAO must report by September 30, 2027, on program reach and effectiveness, estimating eligible populations, service trends, barriers to access, and cost‑effectiveness with respect to patient outcomes (blood pressure, cholesterol, diabetes, obesity). That directed evaluation is intended to produce a near‑term evidence base to inform future funding and program design.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Underserved and low‑income women who already access breast and cervical screening—these women can receive added cardiovascular risk screening and education at trusted community sites, lowering access barriers to prevention.
- State and local public health programs that administer section 1501 grants—supplemental funds let them broaden service portfolios, strengthen data collection, and potentially improve local cardiovascular outcomes.
- Community health centers and federally qualified health centers—if designated by the Secretary, these sites can integrate prevention services into routine care and capture reimbursement opportunities tied to improved metrics.
- Policymakers and public health researchers—the GAO study and mandated reporting will create new evaluative data to guide future investment decisions and best practice dissemination.
Who Bears the Cost
- The federal government—appropriations of up to $250 million across five years fund the program; actual outlays depend on Congress providing those funds in appropriations bills.
- Section 1501 grantees and other providers—program expansion will require staff time, training, IT upgrades, referral network development, and data collection capacity that may not be fully covered by grants.
- CDC and HHS—agency staff will need to develop grant criteria, monitoring and reporting requirements, and guidance for defining ‘high‑risk’ populations and acceptable evidence‑based interventions.
- State health systems and safety‑net providers—if referrals generate additional clinical care needs, local systems may see increased demand for follow‑up treatment not covered by the supplemental grants.
Key Issues
The Core Tension
The central dilemma is between rapid, flexible expansion to reach more high‑risk women (via Secretary discretion and a broad provider definition) and the need for clear, standardized eligibility, service, and measurement rules to ensure equitable access, consistent quality of care, and reliable evaluation—solving one side weakens the other.
Two practical implementation questions will drive the program's early success. First, the Secretary’s discretion to define ‘other women who are high‑risk’ and to authorize additional providers creates flexibility but also uncertainty: states and providers need clear criteria and guidance quickly to design equitable outreach.
Second, the authorization of $250 million over five years is a finite envelope; without clarity on per‑grantee award sizes, matching requirements, or administrative set‑asides, grantees may face hard choices between offering screenings broadly versus investing in comprehensive follow‑up and data systems.
The bill ties funding to evaluation and asks GAO for a cost‑effectiveness analysis, but it leaves key methodological choices open—what constitutes a measurable outcome, the appropriate time horizon for clinical changes, and how to account for selection bias among women who participate. The statutory requirement that grantees provide referrals and follow‑up ‘to the extent practicable’ acknowledges resource limits but could produce uneven care pathways across jurisdictions, undermining program equity and complicating cross‑site comparisons in evaluation work.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.